Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Clin Exp Obstet Gynecol ; 41(5): 525-9, 2014.
Article in English | MEDLINE | ID: mdl-25864252

ABSTRACT

PURPOSE OF INVESTIGATION: Pain control and early ambulation are two important postoperative goals. Strategies that decrease morphine use while increasing ambulation have the potential to decrease postoperative complications. In this study the authors sought to determine the effect of an abdominopelvic binder on postoperative morphine use, pain, and ambulation in the first day after surgery. MATERIALS AND METHODS: The authors randomly assigned 75 patients undergoing abdominal gynecologic surgery to either binder or not after surgery. Demographic data and surgical characteristics were collected. Outcome variables included morphine use, pain score, time to ambulation, and number of ambulations. RESULTS: A group at high risk for decreased mobility was identified and the binder increased the number of ambulatory events by 300%, 260%, and 240% in patients with vertical incisions, age over 50 years, and complex surgeries, respectively. Morphine use and pain scores were not significantly different. CONCLUSION: The binder increased ambulations in the subset of patients at the highest risk for postoperative complications: elderly, cancer patients, and vertical incisions. Routine use of the binder may benefit particularly high-risk gynecologic surgical patients.


Subject(s)
Abdominal Wall/surgery , Gynecologic Surgical Procedures/methods , Neoprene/pharmacology , Pain, Postoperative/prevention & control , Postoperative Care/methods , Abdominal Wound Closure Techniques , Adult , Female , Follow-Up Studies , Humans , Middle Aged , Morbidity/trends , Pain Measurement , Pain, Postoperative/diagnosis , Pain, Postoperative/epidemiology , Retrospective Studies , Texas/epidemiology , Treatment Outcome
2.
J Reprod Med ; 46(10): 929-32, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11725741

ABSTRACT

BACKGROUND: Female genital tract tuberculosis (TB) is a common cause of infertility in developing countries. It is a paucibacillary form of the disease of which smears and cultures are usually negative. CASE: We were able to use polymerase chain reaction (PCR) amplification of Mycobacterium tuberculosis DNA to support a clinical and histologic diagnosis of a typical case of culture negative female genital tract TB. CONCLUSION: PCR may be a useful adjunct to diagnostic efforts in gynecologic tuberculosis.


Subject(s)
DNA, Bacterial/genetics , Mycobacterium tuberculosis/genetics , Polymerase Chain Reaction , Tuberculosis, Female Genital/diagnosis , Tuberculosis, Female Genital/genetics , Adult , Diagnosis, Differential , False Negative Reactions , Female , Humans , Mycobacterium tuberculosis/pathogenicity , Peritoneum/microbiology
3.
Obstet Gynecol Surv ; 56(9): 567-75, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11524622

ABSTRACT

The incidence of cervical adenocarcinoma in situ is increasing in frequency, and our limited knowledge about this lesion presents the physician with a therapeutic dilemma. Treatment for this lesion has included conservative therapy, large loop excision or cold-knife cone biopsy, or definitive therapy consisting of hysterectomy. But, rates of residual adenocarcinoma in situ after cone biopsy with negative margins vary from 0% to 40%, and residual disease rates as high as 80% have been noted when the margins are positive. Despite these recent data on follow-up after conservative therapy such as cone biopsy, it seems that this method is safe and gaining acceptance by many physicians and patients. However, the short follow-up duration and small number of patients limit the conclusions of many studies. The relative infrequency of this diagnosis has precluded extensive clinical experience with the natural history of this lesion.


Subject(s)
Adenocarcinoma , Carcinoma in Situ , Uterine Cervical Neoplasms , Adenocarcinoma/diagnosis , Adenocarcinoma/epidemiology , Adenocarcinoma/therapy , Biopsy , Carcinoma in Situ/diagnosis , Carcinoma in Situ/epidemiology , Carcinoma in Situ/therapy , Female , Humans , Hysterectomy , Neoplasm Recurrence, Local , Neoplasm, Residual , Uterine Cervical Neoplasms/diagnosis , Uterine Cervical Neoplasms/epidemiology , Uterine Cervical Neoplasms/therapy
4.
Gynecol Oncol ; 81(2): 242-6, 2001 May.
Article in English | MEDLINE | ID: mdl-11330957

ABSTRACT

OBJECTIVE: The cyclin-dependent kinase inhibitor p27 has been shown to mediate cell growth arrest in response to various environmental stimuli. p27 protein levels have shown prognostic value in several different types of cancer. We examined the prognostic value of p27 protein expression in endometrial cancer, the most common gynecologic malignancy. METHODS: A total of 95 paraffin-embedded tumor blocks were obtained and stained via immunohistochemical techniques with a monoclonal antibody against p27. Ten high-power fields were evaluated per slide with at least 1000 cells per slide and two slides per specimen evaluated by two reviewers for nuclear and cytoplasmic staining. The specimens were evaluated for associations with age, stage, grade, and histology. Statistical analysis was performed using the Student t test, chi(2) Kaplan-Meier, and likelihood ratios to assess the data and to generate P values. RESULTS: A total of 91 patients met inclusion criteria for statistical analysis. Fifty-three patients were stage I, 13 stage II, 14 stage III and 11 stage IV with a positive stain (>50% of cells) for p27 obtained in 32.1, 23.1, 35.7, and 36.4%, respectively (Student t test P = 0.77). Survival data were available on 24 advanced stage patients. p27 protein immunostaining showed no association with patient survival. We also found no association of p27 staining with age or histology. Notably, we found a trend in increasing staining with increase in grade, particularly with stage I patients. Also, there was an association of the nuclear and cytoplasmic staining and stage (P = 0.05), but it had no correlation with patient survival. CONCLUSION: Our study showed decreased p27 protein staining in endometrial cancers compared to normal endometrial cells. We found that p27 protein staining shows no association with stage, age, or histology and is not prognostic for survival in advanced endometrial cancers. However, there may be a trend associated with increased p27 protein staining with advanced grades of tumors.


Subject(s)
Cell Cycle Proteins , Endometrial Neoplasms/metabolism , Microtubule-Associated Proteins/physiology , Tumor Suppressor Proteins , Cell Nucleus/metabolism , Cyclin-Dependent Kinase Inhibitor p27 , Cytoplasm/metabolism , Endometrial Neoplasms/pathology , Female , Humans , Immunohistochemistry , Microtubule-Associated Proteins/metabolism , Neoplasm Staging , Paraffin Embedding , Prognosis , Subcellular Fractions/metabolism
5.
Am J Obstet Gynecol ; 184(3): 315-21, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11228480

ABSTRACT

OBJECTIVE: The aim of this study was to determine the rates of recurrent dysplasia with longer follow-up durations and to determine whether margin status and other variables were associated with recurrence. STUDY DESIGN: A retrospective chart review was performed for all women who underwent a loop electrosurgical excision procedure at Wilford Hall Medical Center, Lackland Air Force Base, Texas, between January 1993 and December 1994. Extracted information included age, parity, indication for the loop electrosurgical excision procedure, histologic classification of the loop electrosurgical excision procedure specimen, margin status, and whether a "deep" (endocervical) pass had been performed. Follow-up data included findings of repeated cytologic examination, colposcopy, and biopsy if performed. RESULTS: The mean duration of follow-up for all women was 24 months. Margins were positive in 28%, with 73% of these being endocervical. The overall recurrent dysplasia rate was 31%, with a mean time to recurrence of 11.9 months. Participants with any positive margins had a higher recurrence rate than did those with negative margins (47% vs 26%; P = .009). High-grade lesions at the margin were more commonly associated with recurrence than were low-grade lesions relative to those with clear margins (high-grade lesion vs negative margins, 55% vs 26%; P = .003; low-grade lesion vs negative margins, 36% vs 26%; P = .34). Recurrence was not associated either with the performance of an endocervical pass or with the histologic diagnosis of the loop electrosurgical excision procedure specimen. CONCLUSION: With comprehensive long-term follow-up, positive margins on loop electrosurgical excision procedure specimens were shown to be a risk factor for recurrence of cervical dysplasia, particularly when high-grade lesions were seen at the margin. Recurrence was also considerable among women with negative margins. Women should be counseled regarding this risk, and the importance of follow-up should be emphasized.


Subject(s)
Electrosurgery , Uterine Cervical Dysplasia/surgery , Adolescent , Adult , Aged , Biopsy , Cervix Uteri/pathology , Colposcopy , Female , Follow-Up Studies , Histocytochemistry , Humans , Middle Aged , Papillomaviridae/isolation & purification , Recurrence , Retrospective Studies , Uterine Cervical Dysplasia/pathology , Vaginal Smears
6.
Cancer ; 91(4): 869-73, 2001 Feb 15.
Article in English | MEDLINE | ID: mdl-11241257

ABSTRACT

BACKGROUND: [corrected] It was the purpose of this study to investigate whether race is an independent prognostic factor in the survival of patients with cervical carcinoma in a health care system with minimal racial bias, and few barriers to access to care. METHODS: Records for patients with a diagnosis of invasive cervical carcinoma from 1988 to 1999 were obtained from the Automated Central Tumor Registry for the United States Military Health Care System. Clinical data including race, age at diagnosis, histology, grade, stage, socioeconomic status, treatment modality, and survival also were obtained. Survival analysis was performed with Kaplan-Meier survival curves. RESULTS: One thousand five hundred fifty-three patients were obtained for review. Sixty-five percent of patients were Caucasian, and 35% were minorities. Of the minorities, 29% were African Americans (AAs). Mean age of diagnosis was similar among AAs and Caucasians, 44 and 42 years, respectively. There was no statistically significant difference between the distribution of age, stage, grade, or histology between Caucasians and AAs. Forty-six percent of patients were treated with surgery and 56% with radiation therapy, with no difference in type of treatment between the Caucasian and AA groups. Five- and 10-year survival rates for Caucasians and AAs were 75%, and 76%, and 64% 65% (P = 0.59), respectively. CONCLUSIONS: In an equal access, unbiased, nonracial environment, race is not an independent predictor of survival for patients with cervical carcinoma. This study has shown, for the first time to the authors' knowledge, that when they receive equal treatment for cervical carcinoma, AA women's survival can approach that of their nonminority counterparts (75% at 10 years).


Subject(s)
Black or African American , Health Services Accessibility , Uterine Cervical Neoplasms/therapy , Black or African American/statistics & numerical data , Female , Humans , Prognosis , Survival Analysis , United States/epidemiology , Uterine Cervical Neoplasms/ethnology , White People/statistics & numerical data
7.
J Low Genit Tract Dis ; 4(1): 30-3, 2000 Jan.
Article in English | MEDLINE | ID: mdl-25950788

ABSTRACT

OBJECTIVES: We set out to determine the clinical significance of atypical immature squamous metaplasia (AIM). METHODS: We performed in a military, hospital-based colposcopy clinic a descriptive, retrospective review of patients who had a diagnosis of AIM. Patients were examined at 3- to 4-month intervals for at least 1 year after a diagnosis of AIM was established. A gynecological pathologist reviewed all histological and cytological specimens. Initial histological or cytological specimens were tested for the presence of HPV DNA using in situ hybridization. RESULTS: High-risk HPV DNA types 16 or 18 were detected in 3% of patients with AIM. Concurrent cervical intraepithelial neoplasia 3 (CIN3) was noted in 3% of patients with AIM. One-third of patients with initially diagnosed AIM had complete resolution of this lesion after 1 year of follow-up. CONCLUSIONS: This descriptive, retrospective review shows that AIM does not appear to be associated with high-risk HPV DNA or with CIN3. In this limited study, a concurrent diagnosis of AIM likely does not influence the 1-year behavior of CIN. The degree of CIN should dictate treatment recommendations. A larger prospective trial is needed.

8.
Gynecol Oncol ; 73(2): 331-4, 1999 May.
Article in English | MEDLINE | ID: mdl-10329057

ABSTRACT

Primary peritoneal serous adenocarcinoma with predominating psammoma bodies, psammocarcinoma, is a very rare tumor with only seven cases documented in the English literature. Pathological classification of this entity was established in 1990 and clinical behavior of this tumor is uncertain. Based on limited data these tumors appear to behave similarly to low malignant potential tumors of the ovary. This case describes a 59-year-old woman who underwent exploratory laparotomy for a large upper abdominal cystic mass. Findings included a large tumor mass involving the gastrocolic omentum and dense small bowel adhesions. The patient had normal ovaries and was debulked to no macroscopic disease. Final pathologic diagnosis confirmed a stage IIIC primary peritoneal psammocarcinoma. The patient has received no adjunctive therapy and is without evidence of disease 2 years after surgery. Primary peritoneal psammocarcinoma is a neoplasm which can mimic serous adenocarcinoma of the ovary. In contrast, primary peritoneal psammocarcinoma appears to behave in an indolent fashion. Primary surgical debulking should be attempted, while the utility of postoperative chemotherapy remains unknown.


Subject(s)
CA-125 Antigen/blood , Cystadenocarcinoma, Serous/diagnosis , Peritoneal Neoplasms/diagnosis , Abdomen , Cystadenocarcinoma, Serous/blood , Female , Humans , Middle Aged , Peritoneal Neoplasms/blood
9.
Gynecol Oncol ; 72(3): 392-401, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10053112

ABSTRACT

OBJECTIVE: Utilizing ovarian cancer cell lines, we examined the effect of IFN-gamma on each type of TNF receptor. Additionally, we sought to determine the effect of receptor modulation on TNF-alpha-mediated cytolysis. METHODS: Ovarian cancer cell lines Caov-3, A2780, and SK-OV-3 were employed. The number of TNF receptors was determined by a TNF-alpha binding assay utilizing 125I-labeled TNF-alpha. Monoclonal antibodies specific for the 55- to 60-kDa (TR60) and the 75- to 80-kDa (TR80) TNF receptors were used to determine the relative density of each receptor type. Northern blot analyses were performed employing cDNA probes for the TR60 and TR80 mRNAs. To elucidate which receptor(s) was responsible for mediating the signal for cytolysis, 24-h MTT cytolytic assays were performed in the presence of receptor-specific monoclonal antibodies. RESULTS: IFN-gamma treatment resulted in an increase in TNF receptors in the cell lines A2780 and Caov-3 (P < 0.001), but not SK-OV-3. Northern blot analyses suggested distinct regulatory mechanisms for the two receptors. In Caov-3 and SK-OV-3 cells a synergistic increase in TNF-alpha-mediated cytolysis was seen when cells were pretreated with IFN-gamma. In both cell lines, pretreatment with IFN-gamma markedly enhanced the ability of the TR60 receptor to mediate cell lysis. Conversely, under similar treatment conditions, the TR80 receptor did not appear capable of generating a cytolytic signal. CONCLUSIONS: TNF receptor modulation by IFN-gamma appears to be unique to individual cell lines. The TR60 TNF receptor plays a central role in the synergistic cytolytic effects of IFN-gamma and TNF-alpha. Sequential therapy with IFN-gamma and TNF-alpha and specific TNF receptor activation may provide novel translational strategies for the use of cytokines in the treatment of ovarian cancer.


Subject(s)
Interferon-gamma/pharmacology , Ovarian Neoplasms/immunology , Receptors, Tumor Necrosis Factor/drug effects , Tumor Necrosis Factor-alpha/pharmacology , Binding, Competitive , Blotting, Northern , Cytotoxicity Tests, Immunologic , Dose-Response Relationship, Immunologic , Female , HeLa Cells , Humans , Iodine Radioisotopes , RNA, Messenger/analysis , Receptors, Tumor Necrosis Factor/genetics , Receptors, Tumor Necrosis Factor/physiology , Tumor Cells, Cultured/immunology , Tumor Necrosis Factor-alpha/metabolism
11.
Obstet Gynecol ; 89(5 Pt 2): 854-6, 1997 May.
Article in English | MEDLINE | ID: mdl-9166350

ABSTRACT

BACKGROUND: Up to 20% of ovarian epithelial tumors are classified as being of low malignant potential. Most of these low malignant potential tumors are detected at an early stage and have an excellent prognosis. This is a report of a woman with cardiac metastasis from an ovarian low malignant potential tumor. CASE: This case describes a 53-year-old woman who presented with congestive heart failure and was found to have a recurrent stage III ovarian tumor of low malignant potential. A transesophageal echocardiogram revealed compression of the inferior vena cava and a mass encompassing the right atrium. Findings at autopsy confirmed a low malignant potential ovarian tumor thrombus involving the inferior vena cava and right atrium. CONCLUSION: Ovarian low malignant potential tumors can metastasize in an aggressive manner. A transesophageal echocardiogram may be useful when the diagnosis of cardiac tumor thrombus is considered.


Subject(s)
Carcinoma/secondary , Heart Neoplasms/secondary , Neoplasm Recurrence, Local/pathology , Ovarian Neoplasms/pathology , Carcinoma/diagnostic imaging , Echocardiography, Transesophageal , Fatal Outcome , Female , Heart Failure/etiology , Heart Neoplasms/diagnostic imaging , Humans , Middle Aged , Neoplasm Staging , Thrombosis/etiology , Vena Cava, Inferior
12.
Am J Obstet Gynecol ; 174(1 Pt 1): 145-53, 1996 Jan.
Article in English | MEDLINE | ID: mdl-8571998

ABSTRACT

OBJECTIVE: Our purpose was to define the expression of tumor necrosis factor receptors on ovarian cancer cells and determine what role these receptors play in tumor necrosis factor-alpha-mediated cytolysis. STUDY DESIGN: Cell surface expression of tumor necrosis factor-alpha receptors was determined on ovarian cancer cell lines Caov-3, SK-OV-3, NIH:OVCAR-3, and A2780 by a tumor necrosis factor-alpha-binding assay that used iodine 125-labeled tumor necrosis factor-alpha. Monoclonal antibodies specific for the 55 to 60 kd (TR60) and 75 to 80 kd (TR80) tumor necrosis factor receptors were used to determine the relative density of each receptor type. To elucidate which receptor(s) was responsible for mediating the signal for cytolysis, 24-hour MTT cytolytic assays that used tumor necrosis factor-alpha and emetine were performed in the presence or absence of receptor-specific monoclonal antibodies. RESULTS: The four ovarian cell lines expressed a similar number of surface receptors, 4500 to 7000 per cell, had similar dissociation constants, 0.3 to 0.6 nmol/L, and expressed predominately the TR60 receptor subtype. Receptor function studies showed that the presence of the monoclonal antibody to the TR60 receptor completely inhibited tumor necrosis factor-alpha-mediated cytolysis, whereas the monoclonal antibody to the TR80 receptor only partially blocked cytolysis. CONCLUSIONS: Ovarian cancer cell lines express both tumor necrosis factor receptors, with the TR60 receptor being the dominant subtype. Tumor necrosis factor-alpha-mediated cytolysis appears to be dependent on the presence of a functional TR60 receptor. The TR80 receptor does not appear requisite for cytolysis; however, a complementary role cannot be excluded. Manipulation of tumor necrosis factor receptor subtypes on ovarian cancer cells may enhance the cytotoxic effects, thus improving the therapeutic efficacy of tumor necrosis factor-alpha.


Subject(s)
Antineoplastic Agents/pharmacology , Ovarian Neoplasms/pathology , Receptors, Tumor Necrosis Factor/physiology , Tumor Necrosis Factor-alpha/pharmacology , Antibodies, Monoclonal/pharmacology , Binding, Competitive , Cross-Linking Reagents , Emetine/pharmacology , Female , Humans , Iodine Radioisotopes , Ovarian Neoplasms/chemistry , Protein Synthesis Inhibitors/pharmacology , Receptors, Tumor Necrosis Factor/antagonists & inhibitors , Receptors, Tumor Necrosis Factor/metabolism , Tumor Cells, Cultured , Tumor Necrosis Factor-alpha/metabolism
13.
Fertil Steril ; 61(5): 872-9, 1994 May.
Article in English | MEDLINE | ID: mdl-8174724

ABSTRACT

OBJECTIVE: To examine the relative efficacies of leuprolide acetate (LA) and hCG in inducing ovulation and a normal luteal phase during clomiphene citrate (CC)-stimulated superovulation cycles. DESIGN: Prospective, randomized, blinded, and cross-controlled in consecutive cycles. SETTING: Large military tertiary care center. PATIENTS: Twenty-one ovulatory patients undergoing superovulation with CC and IUIs for the treatment of unexplained or male factor infertility. INTERVENTIONS: Clomiphene citrate (100 mg/d) on cycle days 5 through 9 in both of the study cycles. Administration of 2 mg SC LA in one cycle and 10,000 IU IM hCG in another cycle for induction of the midcycle surge. MAIN OUTCOME MEASURES: Serum LH, FSH, E2, and P levels every 12 hours for 36 hours after administration of either LA or hCG to characterize the midcycle hormonal dynamics. Luteal phase duration and serum P levels during the midluteal phase were used to estimate the adequacy of the luteal phase. Serial ultrasounds also were done to determine the incidence of luteinized unruptured follicle syndrome. RESULTS: Serum FSH levels in the periovulatory interval were significantly higher after the administration of LA. There were no differences in the periovulatory E2 or P levels or the incidence of sonographic evidence of ovulation after administration of either LA or hCG. Although midluteal serum P levels were higher in the cycles in which hCG was administered, all 42 treatment cycles had adequate luteal phases as assessed by luteal phase duration and three midluteal P levels. Ongoing pregnancies occurred after both LA- and hCG-stimulated cycles. CONCLUSION: Leuprolide acetate and hCG were equivalent in their abilities to induce ovulation. Further evaluation of the adequacy of the luteal phase and the ensuing pregnancy rates after LA induction of an endogenous gonadotropin surge are indicated.


Subject(s)
Chorionic Gonadotropin/therapeutic use , Clomiphene/pharmacology , Leuprolide/therapeutic use , Ovulation Induction , Ovulation/drug effects , Adult , Double-Blind Method , Estradiol/blood , Female , Follicle Stimulating Hormone/blood , Humans , Incidence , Luteal Phase/physiology , Luteinizing Hormone/blood , Ovulation/physiology , Progesterone/blood , Prospective Studies
14.
Fertil Steril ; 60(2): 242-6, 1993 Aug.
Article in English | MEDLINE | ID: mdl-8339818

ABSTRACT

OBJECTIVE: To evaluate the relationship between the E2 response during the clomiphene citrate (CC) challenge test and ovarian responsiveness to exogenous gonadotropins. DESIGN: Performance of a CC challenge test followed by ovulation induction with exogenous gonadotropins as part of participation in an assisted reproduction program. SETTING: Assisted reproduction program in a large military tertiary care center. PATIENTS: Two hundred forty-seven women between the ages of 24 and 39 years with normal CC challenge tests within 1 year of their assisted reproduction cycle. INTERVENTIONS: Performance of CC challenge tests and ovulation induction with exogenous gonadotropins as a component of an assisted reproduction cycle. MAIN OUTCOME MEASURES: Correlation of the E2 response during the CC challenge test and peak E2, the duration of stimulation, number of ampules of exogenous gonadotropins, number of mature follicles, number of mature oocytes recovered, and fertilization and pregnancy rates in an assisted reproduction program. RESULTS: No correlation exists between the E2 response during the CC challenge test and any of the parameters evaluated. CONCLUSION: Monitoring of the E2 response during the CC challenge test did not predict ovarian responsiveness or pregnancy rates in patients participating in an assisted reproduction program and one may choose not to include it in routine testing.


Subject(s)
Clomiphene , Estradiol/blood , Infertility, Female/diagnosis , Adult , Female , Fertilization , Fertilization in Vitro , Gamete Intrafallopian Transfer , Humans , Ovulation Induction , Pregnancy , Pregnancy Outcome , Regression Analysis , Zygote Intrafallopian Transfer
15.
Obstet Gynecol ; 81(1): 127-30, 1993 Jan.
Article in English | MEDLINE | ID: mdl-8416447

ABSTRACT

OBJECTIVE: To determine whether patients with less than optimal Papanicolaou tests constitute a low-risk group for developing subsequent abnormalities and thus do not need early repeat screening. METHODS: For the 10-month period October 1989 to August 1990, all screening Papanicolaou tests were classified by the 1988 Bethesda System. Tests designated as less than optimal solely on the basis of lack of an endocervical component were the subject of the study. Prenatal patients with less than optimal tests had repeat tests at the postpartum visit (delayed-repeat group), whereas gynecologic less than optimal tests were repeated within 4 weeks (early-repeat group). The frequency of cytologic abnormalities in our routine gynecologic population was compared with that for both the delayed- and early-repeat testing groups. RESULTS: The less than optimal rate in obstetric patients was 10.2% (153 of 1492), which was significantly higher than the 5.6% rate (473 of 8411) in the routine gynecologic population (P < .0001). The rates of dysplasia or combined abnormalities (dysplasia, human papillomavirus, or atypia) in the delayed-repeat group did not differ significantly from those in the routine gynecologic population (P = .69 and P = .33, respectively). However, the rates of dysplasia or combined abnormalities were significantly lower in the early-repeat group than in the routine gynecologic population (P = .02 and P = .003, respectively). CONCLUSIONS: Less than optimal cervical cytologies occurred almost twice as often in obstetric as in gynecologic patients. Prenatal less than optimal test results were not associated with important cervical pathology, and repeat testing may safely be deferred until postpartum. In addition, early repeat testing in gynecologic patients is a low-yield procedure.


Subject(s)
Papanicolaou Test , Uterine Cervical Neoplasms/diagnosis , Vaginal Smears , Adult , Cervix Uteri/pathology , Cytodiagnosis , Female , Humans , Middle Aged , Prenatal Care , Risk Factors , Uterine Cervical Dysplasia/diagnosis , Uterine Cervical Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...